Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The N-methyl-d-aspartate receptor (NMDAR) antagonists including phencyclidine (PCP) and ketamine produce cognitive deficits in rodents and humans. We previously reported that (R)-ketamine produced the beneficial effects compared to (S)-ketamine in several animal models including depression. Here we compared the effects of two enantiomers of ketamine on cognitive deficits in mice after repeated administration of PCP. PCP (10 mg/kg/day for 10 days)-induced cognitive deficits were ameliorated by subsequent repeated intermittent administration of (R)-ketamine (10 mg/kg/day, twice weekly for 2-weeks), but not (S)-ketamine. Western blot analysis showed decreased levels of brain-derived neurotrophic factor (BDNF) and decreased ratio of phosphorylated-TrkB (p-TrkB) to TrkB in the prefrontal cortex (PFC) and hippocampus of PCP-treated mice. Furthermore, PCP-induced reduction of BDNF and p-TrkB/TrkB ratio in the PFC and hippocampus of PCP-treated mice was ameliorated by subsequent intermittent administration of (R)-ketamine. Interestingly, the beneficial effects of (R)-ketamine were blocked by pretreatment with TrkB inhibitor ANA-12. These findings suggest that (R)-ketamine could ameliorate PCP-induced cognitive deficits via activation of BDNF-TrkB signaling in the brain. Therefore, (R)-ketamine could be a potential therapeutic drug for cognitive impairment in patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationA Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Cazorla, M., Prémont, J., Mann, A., Girard, N., Kellendonk, C., & Rognan, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43992 · Cited by 392
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
Self-citationJavitt, D. C., Zukin, S. R., Heresco-Levy, U., & Umbricht, D. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs069 · Cited by 322
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationYang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citation
Research works printed but not linked: 41
- Chaki, 2017, Beyond ketamine: new approaches to the development of safer antidepressants, Curr. Neuropharmacol., 15, 963, 10.2174/1570159X15666170221101054 · DOI · Paper page
- Coyle, 2017, Schizophrenia: basic and clinical, Adv. Neurobiol., 15, 255, 10.1007/978-3-319-57193-5_9 · DOI
- Domino, 2010, Taming the ketamine tiger. 1965, Anesthesiology, 113, 678, 10.1097/ALN.0b013e3181ed09a2 · DOI · Paper page
- Domino, 2012, Phencyclidine/schizophrenia: one view toward the past, the other to the future, Schizophr. Bull., 38, 914, 10.1093/schbul/sbs011 · DOI · Paper page
- Fujita, 2019, MPTP-induced dopaminergic neurotoxicity in mouse striatum is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling, Psychopharmacology
- Goff, 2011, The treatment of cognitive impairment in schizophrenia, Pharmacol. Biochem. Behav., 99, 245, 10.1016/j.pbb.2010.11.009 · DOI · Paper page
- Green, 1996, What are the functional consequences of neurocognitive deficits in schizophrenia?, Am. J. Psychiatry, 153, 321, 10.1176/ajp.153.3.321 · DOI · Paper page
- Hashimoto, 2014, Targeting of NMDA receptors in new treatments for schizophrenia, Expert Opin. Ther. Targets, 18, 1049, 10.1517/14728222.2014.934225 · DOI · Paper page
- Hashimoto, 2016, R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity, Psychol. Med., 46, 2449, 10.1017/S0033291716000969 · DOI · Paper page
- Hashimoto, 2016, Ketamine’s antidepressant action: beyond NMDA receptor inhibition, Expert Opin. Ther. Targets, 20, 1389, 10.1080/14728222.2016.1238899 · DOI · Paper page
- Hashimoto, 2019, Recent advances in the early intervention in schizophrenia: future direction from preclinical findings, Curr. Psychiatr. Rev., 21, 75
- Hashimoto, 2007, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors, Neuropsychopharmacology, 32, 514, 10.1038/sj.npp.1301047 · DOI
- Hashimoto, 2005, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol, Eur. J. Pharmacol., 519, 114, 10.1016/j.ejphar.2005.07.002 · DOI
- Hashimoto, 2008, Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711, Biol. Psychiatry, 63, 92, 10.1016/j.biopsych.2007.04.034 · DOI
- Hashimoto, 2013, Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders, Eur. Arch. Psychiatry Clin. Neurosci., 263, 367, 10.1007/s00406-013-0399-y · DOI · Paper page
- Hida, 2015, Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D₃-5-HT₂A and D₁-NMDA receptors in the mPFC, Neuropsychopharmacology, 40, 601, 10.1038/npp.2014.207 · DOI · Paper page
- Javitt, 1991, Recent advances in the phencyclidine model of schizophrenia, Am. J. Psychiatry, 148, 1301, 10.1176/ajp.148.10.1301 · DOI · Paper page
- Jentsch, 1999, The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia, Neuropsychopharmacology, 20, 201, 10.1016/S0893-133X(98)00060-8 · DOI · Paper page
- Kaur, 2019, Esketamine: a glimmer of hope in treatment-resistant depression, Eur. Arch. Psychiatry Clin. Neurosci.
- Krystal, 1994, Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, Arch. Gen. Psychiatry, 51, 199, 10.1001/archpsyc.1994.03950030035004 · DOI · Paper page
- Krystal, 2019, Ketamine: a paradigm shift for depression research and treatment, Neuron, 101, 774, 10.1016/j.neuron.2019.02.005 · DOI · Paper page
- Li, 2018, The effects of donepezil on phencyclidine-induced cognitive deficits in a mouse model of schizophrenia, Pharmacol. Biochem. Behav., 175, 69, 10.1016/j.pbb.2018.09.006 · DOI
- Lin, 2019, Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress, Front. Psych., 10, 93, 10.3389/fpsyt.2019.00093 · DOI
- Lin, 2019, Novel treatment for the hardest-to-treat schizophrenia: dual action of NMDA receptor and antioxidant, Curr. Drug Targets
- Man, 2018, Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia, Psychiatry Res., 263, 1, 10.1016/j.psychres.2018.02.034 · DOI
- Masaki, 2019, (R)- and (S)-ketamine induce differential fMRI responses in conscious rats, Synapse, 73, 10.1002/syn.22126 · DOI · Paper page
- McShane, 2019, Esketamine and the need for a new type of registry for drugs with abuse potential, Am. J. Psychiatry, 176, 966, 10.1176/appi.ajp.2019.19060631 · DOI
- Morris, 2005, PCP: from pharmacology to modelling schizophrenia, Curr. Opin. Pharmacol., 5, 101, 10.1016/j.coph.2004.08.008 · DOI · Paper page
- Nakazawa, 2019, The origin of NMDA receptor hypofunction in schizophrenia, Pharmacol. Ther.
- Ren, 2015, BDNF–TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms, Transl. Psychiatry, 5, e666, 10.1038/tp.2015.157 · DOI · Paper page
- Shirai, 2015, Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood, PLoS One, 10, 10.1371/journal.pone.0127244 · DOI · Paper page
- Singh, 2017, Ketamine treatment for depression: opportunities for clinical innovation and ethica foresight, Lancet Psychiatry, 4, 419, 10.1016/S2215-0366(17)30102-5 · DOI · Paper page
- Snigdha, 2011, Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain, J. Mol. Neurosci., 43, 337, 10.1007/s12031-010-9447-5 · DOI · Paper page
- Tian, 2018, Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine, Pharmacol. Biochem. Behav., 172, 17, 10.1016/j.pbb.2018.07.003 · DOI · Paper page
- Yang, 2018, Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model, Biol. Psychiatry, 83, 18, 10.1016/j.biopsych.2017.05.016 · DOI · Paper page
- Yang, 2019, Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia, Psychiatry Res., 273, 528, 10.1016/j.psychres.2019.01.051 · DOI · Paper page
- Yoshimi, 2014, Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors, Pharmacol. Biochem. Behav., 124, 245, 10.1016/j.pbb.2014.06.008 · DOI
- Zhang, 2019, An update on ketamine and its two enantiomers as rapid-acting antidepressants, Expert. Rev. Neurother., 19, 83, 10.1080/14737175.2019.1554434 · DOI · Paper page
- Zhang, 2012, Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia, Psychopharmacology, 222, 277, 10.1007/s00213-012-2643-y · DOI
- Zhang, 2014, R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine, Pharmacol. Biochem. Behav., 116, 137, 10.1016/j.pbb.2013.11.033 · DOI · Paper page
- Zhang, 2018, Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study, Psychopharmacology, 235, 1191, 10.1007/s00213-018-4835-6 · DOI
Cited by
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
“deficits in mice were ameliorated after subsequent repeated intermittent administration of arketamine, but not esketamine, and that these effects were mediated by BDNF–TrkB activation [173].”
BackgroundSelf-citationMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
Rafało-Ulińska, A., Brański, P., & Pałucha-Poniewiera, A. (2022) · Pharmaceuticals · doi:10.3390/ph15020125 · Cited by 29
Metadata
- Authors
- Tan, Y., Fujita, Y., Qu, Y., Chang, L., Pu, Y., Wang, S., Wang, X., & Hashimoto, K.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 188
- Pages
- 172839
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2996581715
- Cited by
- 45
- References
- 17
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- Japan Agency for Medical Research and Development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. https://app.cochat.ai/papers/10.1016/j.pbb.2019.172839
- The paper
- Tan, Y., Fujita, Y., Qu, Y., Chang, L., Pu, Y., Wang, S., Wang, X., & Hashimoto, K. (2020). Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent repeated intermittent administration of (R)-ketamine, but not (S)-ketamine: Role of BDNF-TrkB signaling. Pharmacology Biochemistry and Behavior. https://doi.org/10.1016/j.pbb.2019.172839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.